Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169671 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
A Phase 1 study, sponsored by LeonaBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05169671 is a Phase 1 study that has completed, run by LeonaBio. The registered enrollment target is 32 participants.
The verdict
NCT05169671, a Phase 1 study, has completed, sponsored by LeonaBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.
Interventions
- DRUG Placebo
- DRUG ATH-1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2022-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05169671
The ClinicalTrials.gov registry entry for NCT05169671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LeonaBio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05169671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05169671 about?
NCT05169671 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics Study of ATH-1020". This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.
What is the current status of trial NCT05169671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-03-30. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT05169671?
The interventions under investigation include: Placebo (DRUG), ATH-1020 (DRUG).
Who is sponsoring clinical trial NCT05169671?
This trial is sponsored by LeonaBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.